One reason that some people are prone to calcium oxalate nephrolithiasis is that they produce urine that is subnormal in its ability to inhibit the growth of calcium oxalate crystals. We have identified in human urine a glycoprotein (GCI) that inhibits calcium oxalate crystal growth strongly, and at low concentrations (10-' M); in this study, we have isolated GCI molecules from the urine of normal people and patients with calcium oxalate stones. GCI from stone formers is abnormal in three ways: (1) it contains no detectable y-carboxyglutamic acid (Gla), whereas normal GCI contains 2-3 residues of Gla per mole; (2) about half of the GCI in urine of patients inhibits crystal growth 4-20 times less than normal GCI as judged by its performance in a kinetic growth assay, in vitro; (3) at the air-water interface, patient GCI has a film collapse pressure approximately half of normal. GCI molcules from the urine of patients with calcium oxalate nephrolithiasis are intrinsically abnormal, and these abnormalities could play a role in the genesis of stones.
Introduction
Human urine inhibits the growth of calcium oxalate monohydrate crystals. Added at dilutions of even 1:100, urine greatly slows the rate at which calcium oxalate monohydrate crystals grow in a metastably supersaturated calcium oxalate solution (1) (2) (3) (4) (5) (6) . The upper limit of metastability for calcium oxalate is higher in urine than in simple salt solutions (7) , because urine inhibits the process of nucleation-i.e., the transformation of solution ions into a solid phase-and slows the growth of very small nuclei so they cannot be detected.
Although citrate and inorganic pyrophosphate are present in urine at concentrations sufficient to inhibit calcium oxalate monohydrate crystal growth-0.5-1 mM and 1-2 ,uM, respectively, they account for little of the crystal growth inhibition produced by urine (2) . Exhaustive dialysis of urine removes both molecules, yet reduces crystal growth inhibition by only a few percent (1) . Orthophosphate administered orally increases urine pyrophosphate level, and inhibits the crystal growth in urine of brushite, but not calcium oxalate monohydrate (8) .
The molecules that account for most ofthe inhibitory effects usual properties (10) that we have purified from a culture of human renal cells (I 1), human urine (12) , and rat urine and kidney tissue (13) . The crystal growth inhibitor moleculeswhich we wish to abbreviate as GCI molecules-appear to account for a considerable proportion of the inhibitory effects of urine (12, 13) , and are the focus of this report. We (1) and others (5, 9, 14) have found that urine from stone-forming patients inhibits calcium oxalate crystal growth less than normal urine, and have reasoned that patients who form stones may do so in part because they produce GCT molecules that are less inhibitory than normal ones, or excrete intrinsically normal GOCI molecules in abnormally small quantities. We present here evidence for the former: compared with normal GCI molecules, GCI molecules isolated from the urine ofpatients with nephrolithiasis are less effective as inhibitors; they are also abnormal in their composition, and in their physical properties at the air-water interface.
Methods
Patients and normal subjects. We studied 20 normal people ( I1 women) and 17 consecutive patients (7 women) with recurrent calcium oxalate nephrolithiasis (Table I ). The ages (±SEM) of the women normals and patients (29±5 vs. 41±19) and the men normals and patients (31±8 vs. 39±8) were not different. Patients had no known systemic disease as a cause of stones (15) (16) (17) except for idiopathic hypercalciuria (15) , nor were any taking medications. A single 24-h urine was collected (thymol was used as a preservative) while each person ate a free choice diet. Creatinine was measured as a marker for completeness of collection (18) . Each urine sample was processed separately to isolate GCI molecules; but the small amounts of inhibitor available from any individual made it necessary to perform amino acid and carbohydrate analyses, air waterinterface film balance studies, and kinetic assays ofthe crystal adsorption coefficient on pooled materials from patients and normals.
Isolation ofurine inhibitor. Inhibitors were isolated using a modified version of a method developed in this laboratory (12) . A 24-h urine sample was diluted four times in distilled water to lower its ionic strength below 10 milli-Siemens/cm (mS/cm) (equivalent to 0.05 M NaCI). DEAECellulose equilibrated in 0.05 M Tris-HCl-0.05 M NaCl (pH 7.3) was added and stirred for 30 min at room temperature. The slurry was filtered through a sintered glass filter, the cake was washed with 4 liters of 0.05 M Tris-HCI-0.05 M NaCl (pH 7.3), and the inhibitor was eluted with 400 ml of0.05 M Tris-HCl-0.4 M NaCl (pH 7.3). To dissociate aggregated inhibitors to a monomeric form, the eluate was adjusted to a final concentration of 0.05 M EDTA, pH 7.9, and kept at 4VC for 4 d (11, 12) . After EDTA incubation, the solution was dialyzed against 12 liter of deionized water for 24 h with one change.
The dialyzed solution was applied to a DEAE-cellulose column and eluted with a linear NaCl gradient from 0.1 to 0.4 M in 0.05 M Tris buffer (pH 7.3). The GCI molecules exhibit micro-heterogeneity (12) , in eluting from the DEAE-cellulose colur that fall into the ionic strength ranges o 39 mS, and 40-45 mS. Not every urir (Table I) , but all of the inhibitory mater column was in one of the four regions 
where C, is the concentration of calcium or oxalate at any time, t < te, t, is the time required for the solution and crystals to come to thermodynamic equilibrium, C6 is C, at t = te, and k is the empirical rate constant.
The integrated form is:
C, = (Ci + aCet)/(l + at), where a = k(C, -CQ), and C, is C, at t = 0. Inhibition by chromatographic eluates. During purification, we used a combination of Eqs. 2 and 6 to give a simplified approximation of inhibition (1) that could be used for multiple chromatographic samples:
if C, is called C, when inhibitor is present and C0 when no inhibitor is present, Eq. 7 can be substituted for the values of kI and k, in Eq. 6: Distribution ofA, B, C, and D inhibitors. Since a separate DEAEcellulose chromatography elution was performed for each subject, inhibitor content in each ofthe four regions (A-D) could be calculated for Eq. 8 for each tube and each region; we then plotted for each tube of eluate the inhibition against the ionic conductivity in that tube. The inhibitor assay result in each tube was divided by the total of the assay results for all of the tubes from the chromatogram, to give a percentage, and the total percentage of inhibition was calculated for each ofthe four fractions (A-D) for each urine sample (Table I ). The mean percentage for each of the four fractions was then calculated for the normals and patients using the values in Table I (Fig. 1) . The mean percentages of total inhibitor in the A and C fractions were the same for patients and normals. However, normal urine contained more B and less D inhibitor than urine from patients. Direct quantitative comparisons between individuals, or even fractions, cannot be derived from this simplified expression, as complete kinetic data are approximated by a single 40-min measurement, and both [I] and Z are unknowns. We estimated the individual variability ofthe A-D fraction proportions in one patient and two normals. In 11 samples, the male normal had 22±4, 52±6, 17±4, and 9±2 for %A-D (±SEM), respectively; corresponding percentage values for 11 replicates for the woman normal were 16±3, 36±6, 35±5, and 13±3; for the male patient, values for eight replicates were 17±4, 18±3, 39±7, and 27±6. Coefficients of variation for A-D, respectively, were (in percentage) 62, 36, 68, and 74 for the male normal, 64, 53, 49, and 79 for the woman normal, and 63, 36, 49, and 67 for the patient.
Surface property measurements. The surface pressures ofthe purified When the inhibitor was further purified, the protein concentration was determined by alkaline hydrolysis followed by ninhydrin color reaction for determining absorbance at 570 nm (20) . In both cases, calibration standards were prepared using bovine serum albumin from 10 to 75 ,g. Elution of protein during column chromatography was monitored by absorption at 280 or 230 nm. The salt gradient used in DEAE-cellulose column chromatography was monitored using a conductivity meter (model CDM 83, Radiometer, Copenhagen, Denmark). Carbohydrate analysis. Carbohydrate content was analyzed by gas chromatography (Perkin-Elmer, model 910, with 3% OV-I Superlcoport column, 1/4 (i.d.) and 12' length glass tubing, and flame ionization detector). Materials were hydrolyzed in I N HCG-methanol at 80C for 24 h, acetylated, and trimethylsilylated as described by Clamp et al. (21). Peak areas were measured by electronic integration (Sigma 10 analyzer, Perkin-Elmer Corp.). Mannitol was used as the internal standard. The retention time and response factor for each monosaccharide were established using fucose, glucose, galactose, mannose, glucosamine, galactosamine, mannosamine, glucuronic acid, and N-acetylneuraminic acid.
Amino acid analysis. Amino acid analysis was carried out using a 118 Cl analyzer (Beckman Instruments Inc., Palo Alto, CA) with W-3P resin and lithium citrate buffer after hydrolysis in evacuated-sealed tubes containing 6 N HCl, at 1 10C, for 24 h. The number of Gla residues was determined after 24 h alkaline hydrolysis as described by Hauschka (22) . Elution position and color factor were determined using standard Gla. Using bovine blood coagulation Factor IX (Sigma Chemical Co.) as a known Gla-containing protein, we found 11 residues of Gla per molecule, and a ratio of 0.273 of Gla to glutamic acid residues. This compares favorably with reported values of 12 residues per mole (23) and a ratio of 0.297±0.007 (24) . Tryptophan was determined spectrophotometrically after the method of Beaven and Holiday (25). Molecular weight determination. Molecular weight was determined by Sephacryl S-200 column chromatography (2 x 110 cm) and high performance liquid gel permeation chromatography (HPLC) (HPLC model I 1OA, Beckman Instruments Inc.) using a Toyo-Soda column, TSK-G3000W (1.5 X 600 mm) with 0.05 M Tris-HC1-0. I M NaCI containing 0.02% sodium azide (pH 7.5) as a solvent. The calibration curve was established using bovine serum albumin (68,000 mol wt), ovalbumin (43,000 mol wt), Kunitz soybean trypsin inhibitor (21,000 mol wt), and bovine pancreatic ribonuclease (13,700 mol wt). All ofthe eight inhibitors, patient and normal, A-D, eluted from the Sephacryl column at a K.,.
of0.58-0.59, virtually identical to the position ofthe ribonuclease, 0.585, and indicating a molecular weight of 14,000. Their retention times by high performance liquid chromatography were all 7.8-8 min, indistinguishable from that of ribonuclease, which was 7.8 min, and indicated the same molecular weight (14,000). This is the same molecular weight we have established for the normal B inhibitor in our previous study ( 12) .
Statistical methods. Linear and nonlinear regressions, and tests of significance of differences between groups were performed using standard methods for digital computer (BMDP, UCLA School of Computer Sciences, Los Angeles, CA).
Results
Dissociation constants. Patient and normal inhibitors differed in their dissociation constants as derived from the slopes of the Langmuir isotherm type plots (Fig. 2) . Normal A-D inhibitors all had approximately the same constants, between 1.7 and 5 X I0-7 M. Patient inhibitors A and B had constants in this range, and both constants were lower than those ofcorresponding normal materials (Fig. 2) . However, the C and D inhibitors from patients had higher values (lower affinities for the crystals) than corresponding normal materials (Fig. 2) . The Langmuir isotherm graphs were linear for all materials (Fig. 3, A-D) , and all slopes differed significantly from zero (see legend to Fig. 2) . Since the C and D inhibitors together constituted 46% of the total for patient material (Fig. 1) , about half ofthe inhibitor from patients was of subnormal affinity, i.e., less inhibitory on a molar basis than normal.
Surfaceproperties. The collapse pressures ofpatient inhibitors A-C were below corresponding normal values (Fig. 4, A-C) (Table II) . All other amino acids were present in similar proportions, within 8%, in all four fractions ofpatient and normal inhibitors. As we have reported in the past (1 1-13) , the inhibitors are enriched in aspartic and glutamic acids, and contain few basic (lysine and arginine) and aromatic (tyrosine, phenylalanine, and tryptophan) residues.
Carbohydrates. The inhibitors were from 3.5 to 10.3% carbohydrate (Table III) , and all contained fucose, galactose, mannose, glucose, galactosamine, glucosamine, and N-acetylneuraminic acid, but no glucuronic acid. There were no systematic differences between normal and patient materials.
Discussion
Patients who form calcium oxalate stones seem to produce urinary GCI molecules that inhibit calcium oxalate crystal growth less than normal material. The affinities ofthe C and D fractions of patient inhibitor for the calcium oxalate crystal are below corresponding normals by >20-fold and fourfold, respectively, and the C and D fractions account for 46% ofthe total inhibitor in patient samples. A lesser degree of kinetic crystal growth inhibition at any given concentration means that ifpatients excrete as much inhibitor as normals they will have less total effective inhibition ofcrystal growth, and therefore a greater potential for forming stones. We (1) and others (3, 5, 9, 14) have found less overall inhibition of calcium oxalate crystal growth by urine from stone formers compared with normal; part of this deficit may be due to the intrinsic molecular disorder we describe here.
We divided GCI into four fractions because up to four peaks of inhibition could be eluted from a DEAE-cellulose column; the fractions were chosen to correspond to the positions of the four peaks. The elution of inhibitory molecules from a DEAEcellulose column over a wide range of ionic strengths suggests that GCI may have different molecular forms, and for this reason we refer to GCI molecules throughout this report. One alternative is that the four forms differ in their primary amino acid sequence. Another is that they are all the same peptide, but differ in carbohydrate composition enough to cause heterogeneity of ionic association with the DEAE-cellulose. Differences in Gla could account for a separate D peak in normal GCI, as normal D has no Gla, whereas A to C GCI each contain 2-3 Gla residues. However, none of the patient materials contain Gla, yet they elute in A-D peaks that overlap with those of the normal GCI. The elution position from DEAE-cellulose is strongly related to crystal surface affinity in patient, but not normal samples.
Overall, the reasons for the heterogeneity, and its relationship to function remain to be explored. Also unexplored is the interaction between the four forms. They may act synergistically, or they may combine to form large molecules that are more inhibitory; these are untested possibilities.
Patient inhibitors formed surface films at the air-water interface that were less stable than normal. In general, stable films are formed by molecules that are amphiphilic: they have regions that are strongly hydrophilic-that will tend to remain in ix10-' aqueous solution-and other regions that are hydrophobic, and will resist entering the solution (26) . Presumably, the reduced film stability of patient material reflects a loss of well separated hydrophobic and hydrophilic groups. The biological meaning of the normal surfactant quality of GCI, and its attenuation in patients with stones, is unknown. Perhaps strong film forming proteins coat the crystals and prevent solution ions from reaching the surface.
The patient inhibitors also were abnormal in containing no Gla, an amino acid that is present in normal A, B, and C material. Gla possesses two carboxyl groups at one end, and occurs in blood-clotting proteins (27) , and in a protein found in bone (28). The Gla molecules can bind calcium (29) , and appear essential for the biological activity of prothrombin (30). Their function in GCI is unknown; however, one hypothesis is that they play some role in maintaining the conformation of the molecule. The normal type B inhibitor has an axial ratio of 6:1 (12) , and has a highly organized two-dimensional structure with strong amphiphilic properties that would stabilize it at the air-water interface. The Gla residues could control the conformation of the GCI molecule through calcium binding; aggregation of troponin A (31) and formation of the hydrophobic properties of calmodulin (32) both occur with calcium binding. IfGla residues do stabilize the two-dimensional structure of urine GCI, perhaps through shared binding ofcalcium ions, and ifsuch stabilization separates strongly hydrophobic and hydrophilic regions, the abnormal molecules may have less marked surfactant properties than normal because they lack Gla. Our data strongly support this hypothesis. Collapse pressures of normal A, B, and C GCI, which contain Gla, exceed values for the corresponding materials Values of slopes, which give the affinities of GCI for the crystal surface, are shown in Fig. 2 from patients, which lack Gla. The normal D material, which lacks Gla, has the same collapse pressure as patient D; and both lack Gla. Normal D has the lowest collapse pressure of the four normal GCI molecules. Clearly, this issue can only be resolved by studies beyond the present one, such as deliberate decarboxylation of A or B GCI.
Our finding of no Gla in patient inhibitors contrasts with the study of Lian et al. (33) , who isolated from renal calculi a protein that contains Gla and resembles the ones we describe here. Calcium, but not uric acid stones, contain proteins rich in aspartic and glutamic acids, low in lysine and arginine, and possessing Gla. One ofthem, of 17,000 mol wt, contained 39 residues of Gla per 1,000 amino acids, and 290 and 188 of aspartic and glutamic acids, respectively, per 1,000 amino acid residues; this protein may be very similar to ours.
Why did they find Gla rich proteins in stones, while we found no Gla in our inhibitors? One hypothesis, which we favor, is that stones naturally accumulate and concentrate inhibitors from urine-because the inhibitors stick to the calcium oxalate crystals-so stones become very concentrated with inhibitors. The enrichment allows one to detect Gla proteins that are so subnormal in amount that our methods, based upon urine alone, fail to disclose them. Since the normal inhibitors have Gla, and higher affinity for the calcium oxalate surface, it may be that the Gla proteins that patients do produce are selectively trapped on the stones, so they can be recovered from stones even though they are present in such small amounts in urine as to escape notice. Testing of this notion will require comparison of stone inhibitors to those isolated from urine.
Kidney stone proteins that seem superficially like ours have Furthermore, we separated materials using an inhibition assay and direct monitoring of protein concentration, whereas others (33-36) have followed optical density peaks. Despite their abnormal behavior and composition, patient inhibitors were much like normal ones in amino acid and carbohydrate composition and molecular weight. All of the inhibitors from patients and normals had a high percentage of acidic amino acids, few basic and aromatic amino acid residues, and similar sugars. They are also similar to inhibitor molecules we have purified from cell culture medium (1 1) and rat kidney tissue and urine (13) , suggesting that these proteins have been reasonably stable during evolution.
Our study used pooled materials rather than proteins isolated from individuals, and so our results refer to the average behavior and composition of normal and patient inhibitors. For example, the dissociation constants ofC and D proteins from some patients may be normal, and the constants ofproteins from other patients far more abnormal than the average value we studied. Analogous variability may be present in their interfacial film-forming behavior. In other words, our design precludes statements about heterogeneity among subjects. For Gla contents, this limitation may not be very important, as no patient protein contained the amino acid.
Overall, the present study suggests that a molecular disorder may be responsible for some component of calcium oxalate nephrolithiasis, but the actual basis for the functional disorders Table I and Fig. 1 . N, normal subjects; P, determined. All values are residues per molecule of GCI. 
